Chronic viral hepatitis

International Journal of Clinical Practice

Volumn 54, Issue 7, 2000, Pages 450-456

  Alexander, G ^a   Walsh, K ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; AMINOTRANSFERASE; LAMIVUDINE; RIBAVIRIN;

ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; META ANALYSIS; PRIORITY JOURNAL; RASH; REVIEW; SEROCONVERSION; SLEEP DISORDER; TREATMENT OUTCOME; VIRAL GENETICS; VIRUS HEPATITIS; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HEPATITIS D, CHRONIC; HUMAN; INTERFERON-ALPHA; LIVER TRANSPLANTATION; POLYMERASE CHAIN REACTION;

EID: 0033803772     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. The emerging pattern of post-transfusion hepatitis
2. Isolation of a cDNA clone derived from a blood-borne non-A non-B viral hepatitis-genome
3. A proposed system for the nomlecature of hepatitis C viral genotypes
4. Hepatitis C virus and liver diseases
5. Epidemiology of hepatitis C in the East
6. International Consensus Conference on Hepatitis C
7. Hepatitis C viraemia in United Kingdom blood donors: A multicentre study
8. Transmission of hepatitis C virus by organ transplantation in the United Kingdom
9. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection
10. Hepatitis C virus infection in medical personnel after needlestick accident
11. Hepatitis C virus infection in healthcare workers: Risk of exposure and infection
12. A prospective study of hepatitis C virus infection after needlestick accidents
13. Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug abusers
14. Non-A, non-B hepatitis associated with chronic liver disease in a haemodialysis unit
15. Molecular analysis of intraspousal transmission of hepatitis C virus
16. Histopathology of hepatitis C virus infection
17. Chronic liver disease in central Harlem: The role of alcohol and viral hepatitis
18. Prognosis of hepatitis C: Results of a large prospective cohort study
19. Hepatitis C virus infection and liver disease: Peculiar epidemiological and clinicopathological features
20. Hepatitis C infection in patients with chronic hepatitis B: Curiosity or co-factor?
21. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection
22. The natural history of community-acquired hepatitis C in the United States
23. Clinical outcomes after transfusion-associated hepatitis C
24. Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis
25. Autoimmune hepatitis and hepatitis C virus infection
26. Incidence, character and clinical relevance of mixed cryoglobulinaemia in patients with chronic hepatitis C virus infection
27. A role for hepatitis C virus infection in type II cryoglobulinemia
28. Hepatitis C virus associated membranous glomerulonephritis
29. Hepatitis C virus and porphyria cutanea tarda: Evidence of a strong association
30. Evidence of a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population
31. Increased prevalence of diabetes mellitus in patients with chronic hepatitis C infection
32. Further evidence for an association between non-insulin dependent diabetes mellitus and chronic hepatitis C virus infection
33. Hepatitis C: Diagnostic assays
34. Hepatitis C virus antibodies in chronic active hepatitis: Pathogenetic factor or false-positive result?
35. New kit on the block: Evaluation of second-generation assays for detection of antibody to the hepatitis C virus
36. Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection
37. Importance of age in chronic hepatitis C virus infection
38. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon
39. Meta-analysis of interferon randomised trials in the treatment of viral hepatitis C: Effects of dose and duration
40. Predictors of sustained response, relapse and no response in patients with chronic hepatitis C with interferon-α
41. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C
42. Randomised trial of interferon alfa-2b plus ribavirin versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus: International Hepatitis Interventional Therapy Group (IHIT)
43. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
44. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
45. Interferon alpha therapy for hepatitis C virus infection after liver transplantation
46. Long-term outcome of hepatitis C infection after liver transplantation
47. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C
48. Therapy of chronic hepatitis C after liver transplantation: Multicenter Italian experience
49. Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees
50. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses
51. Lack of protective immunity against reinfection with hepatitis C virus
52. T-lymphocyte response to hepatitis C virus in different clinical courses of infection
53. Mapping of immunodominant CD4 + T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection
54. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile
55. The epidemiology of viral hepatitis in the United States
56. Prevalence of hepatitis B virus infection in the United States: The National Health and Nutrition Examination Surveys, 1976 through 1994
57. Molecular virology and pathogenesis of hepatitis B
58. Acute hepatitis B virus infection: Relation of age to the clinical expression of disease and subsequent development of the carrier state
59. Hepatitis B: Virology, epidemiology, disease, and prevention, and an overview of viral hepatitis
60. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men
61. Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis B
62. The serologic course of hepatitis B surface antigen and e antigen and the development of primary hepatocellular carcinoma in asymptomatic carriers of hepatitis B virus
63. Hepatitis B surface antigen disappearance and hepatitis B surface antigen subtype: A prospective, long-term, follow-up study of Japanese residents of Okinawa, Japan with chronic hepatitis b virus infection
64. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis
65. Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period
66. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: A prospective observation of 2215 patients
67. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection
68. A randomized controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B
69. Long-term remission of chronic hepatitis B after alpha-inteferon therapy
70. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection
71. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: A meta-analysis
72. A one-year trial of lamivudine for chronic hepatitis B
73. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
74. A phase II dose-ranging, placebo-controlled trial of adefovir dipivoxil for the treatment of chronic hepatitis B virus infection
75. Hepatitis B virus reinfection after orthotopic liver transplantation: Serological and clinical implications
76. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis
77. Liver transplantation in European patients with the hepatitis B surface antigen
78. Lamivudine prophylaxis against reinfection in liver transplantation foe hepatitis B cirrhosis
79. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
80. Risk factors for lack of detectable antibody following hepatitis B vaccinations of Minnesota health care workers
81. Hepatitis B vaccine in medical staff of haemodialysis units: Efficacy and subtype cross-protection
82. The prevention of hepatitis B with vaccine: Report of the Centers for Disease Control Multi-Center Efficacy trial among homosexual men
83. Yeast-recombinant hepatitis B vaccine: Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission
84. Protection provided by hepatitis B vaccine in a Yupik Eskimo population: Results of a 10 year study
85. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA
86. Evidence that hepatitis D virus needs hepatitis B virus to cause hepatocellular damage
87. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen: An active and progressive disease unresponsive to immunosuppressive treatment
88. Diagnosis of hepatitis delta virus infection
89. Treatment of chronic hepatitis D with interferon alfa-2a
90. Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis
91. Ribavirin for chronic hepatitis D: A pilot study
92. Lamivudine for chronic delta hepatitis